Abstract 5560
Background
The prognosis of metastatic bone and soft-tissue sarcoma remain distal. VEGFR2 inhibitor (VEGFR2i) has been recently found promising but is limited due to the heterogeneous durability of response.
Methods
From Jan 2016 to Jun 2018, 44 patients with lung metastatic sarcoma, including 32 osteosarcoma, 4 Ewing sarcoma, 3 leiomyosarcoma, 2 chondrosarcoma and 3 other sarcoma, given apatinib treatment were reviewed. Of these patients, extra-pulmonary lesions were noticed in 14 cases including local recurrence (9), bone (3), lymph node (2) and brain (1). A starting 250∼500 mg per day was chosen, with dose adjustment according to the individual tolerability. Progression-free survival (PFS) was accessed by RECIST 1.1 criteria and used to discover the potential predictor of durability of response.
Results
The mean 6 month PFS was 58.9 +/- 8.4%, with the duration of response varying from 1 months to no less than 17 months. 12 of the 44 (27.3%) patients required a long-term dose lowering while the remaining well tolerated or has a dose transient lowering less than 7 days. Adverse effects (AEs) greater than degree 2 was seen in 50.0%, including pneumothorax in 11 cases (25.0%). In 9 of 11 cases with pneumothorax, no or minimal drug discontinuance was conducted, with 5 spontaneous recoveries, 3 recoveries with tube drainage, and 1 thoracic empyema with video-assisted thoracoscopic debridement. Multivariate analysis showed that AEs (HR = 0.29 p = 0.008) and sarcoma type (osteosarcoma vs other, HR = 0.17, p = 0.001) were the independent predictors for PFS with VEGFR2i therapy. Surprisingly, pneumothorax was found to be the strongest predictor among all AEs based on the effect size (HR = 0.29, p = 0.036), indicating that the susceptibility of pneumothorax to VEGFR2i might be a new mechanism-based toxicity biomarker for lung metastatic osteosarcoma.
Conclusions
Our result suggested that pneumothorax is a favorable biomarker for targeting VEGFR2 in lung metastatic sarcoma and we encourage no or minimal drug discontinuation in this circumstance.
Clinical trial identification
Legal entity responsible for the study
Ruijin Hospital, Oncological Orthopaedic Department.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract